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wide, ultimately leading to cirrhosis and hepatocellular carci-
noma. Globally, it is estimated that up to 185 million people
have been infected with HCV [1], and among these, according
to the World Health Organization, 130–150 millions are
chronically infected [2]. Recent estimates place to 700,000
the yearly death toll of liver-related, long-term sequelae of
HCV [3]. In many regions of the world, where access to ther-
apy is available, the number of deaths due to HCV has even
surpassed that due to HIV infection [4]. Antiviral therapy is
available for HCV, with success rates currently above 95%.
A sustained virological response (SVR; undetectable HCV
RNA 12 or 24 weeks after the end of therapy) is associated
with improved clinical outcomes, and large studies have shown
that treatment of chronic hepatitis C with antivirals decreases
the risk of liver-related mortality [5–8].
HCV infection is also associated with several extra-hepatic
manifestations, which add to the morbidity and mortality bur-den of HCV. Patients infected with HCV may develop, among
many other disorders, mixed cryoglobulinemia, insulin resis-
tance, several cardiovascular diseases, fatigue, depression,
and cognitive impairment, translating into a significant public
health impact in terms of both direct and indirect costs [9,10].
The pathogenesis of the extra-hepatic features of HCV is not
always clear and may involve endocrine effects, direct toxic
effects due to HCV replication in extra-hepatic tissues, or dis-
proportionate immune reactions with systemic effects.
According to a recent meta-analysis [10], the most frequent
extrahepatic manifestation occurring in HCV infected persons
is depression, with a pooled prevalence of 24.5% vs. 17.2% in
uninfected controls. Hepatitis C patients have a risk for devel-
oping depression of 2.30 vs. persons without HCV. This find-
ing alone underlines the public health impact of extrahepatic
manifestations of hepatitis C: depression is associated with a
high rate of mortality and health resource use, with estimated
annual direct costs, for the US, of USD 430.7 million USD
[10]. Another major manifestation is represented by type 2 dia-
betes. The pooled prevalence of diabetes in hepatitis C patients
has been estimated at 15%, compared with 10% in the unin-
fected population, with a pooled odds ratio for diabetes of
1.58 vs. controls [10]. According to the same study, the yearly
direct costs associated with the management of diabetes in
HCV-infected persons are even higher than those calculated
for depression, and total to about 443 million USD per year.
Mixed cryoglobulinemia (MC), which is probably the best
known extrahepatic syndrome associated with HCV, affects
as many as 30.1% of HCV-infected persons, vs. 1.9% of unin-
fected controls (with a risk ratio of about 12), but the preva-
lence of symptomatic MC is much lower, i.e. 4.9% (vs. 0%
in controls) [10]. This is nonetheless significant from the clini-
cal standpoint, because MC may lead to severe, life-threaten-
ing complications, such as glomerulonephritis, renal
insufficiency and B-cell lymphoma. HCV has also notable
effects on the health-related quality of life and other patients’
reported outcomes, impacting both physical and psychical
well-beings, with fatigue being significantly increased with
respect to uninfected controls. Thus, overall, the public health
burden of extrahepatic manifestations associated with HCV is
a major one, as underlined by the total estimated annual direct
costs of 1506 million USD for the US alone, a figure where
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A sizable proportion of the costs linked to HCV can be off-
set by viral eradication. A prospective cohort study reported
that patients with chronic HCV infection have an increased
risk of death from both liver- and non-liver-related diseases,
including cardiovascular and renal diseases, compared to unin-
fected persons and those with anti-HCV but undetectable
HCV RNA [7]. Importantly, a multicenter study has shown
that curing HCV with antivirals reduces both liver-and non-
liver-related mortalities [8]. Studies focusing on single extra-
hepatic manifestations have provided convincing evidence in
favor of the benefits of viral clearance. Thus, SVR is associated
with reduced levels of insulin resistance and risk of type 2 dia-
betes, and resolution of most MC-related complications,
including the remission of some forms of HCV-associated B-
cell lymphoma, reduced incidence of stroke and other cardio-
vascular outcomes (especially in the presence of diabetes),
and improved patients’ reported outcomes such fatigue and
health-related quality of life [9].
Thus, it is not surprising that regulatory agencies around
the world have recently approved costly antivirals for treat-
ment of patients with clinically significant extrahepatic mani-
festations, independently of the stage of liver disease. The
advent of well-tolerated interferon-free treatment regimens
has increased the number of patients eligible for therapy,
extending the access to treatment to those in whom interferon
was contraindicated, e.g. because of uncontrolled depression,
severe fatigue, autoimmune disorders and cardiovascular
diseases.
This special issue focuses on some of the most clinically rel-
evant extrahepatic manifestations of HCV infection, with a
detailed discussion on the epidemiology, pathogenesis and
management, written by leading experts in the field. We trust
that it will increase the appreciation of these important clinical
syndromes for whom appropriate management is now
available.
Proper understanding of the pathogenesis of HCV infection
and its effects on organs other than the liver are improving.
This leads to the rise of attention to chronic HCV infection
and its relation to the body systems and effect on the immunity
[11]. Physicians other than hepatologists should be aware
about the role of HCV infection and its extrahepatic effects
helping the diagnosis of unexplained manifestations as arthral-
gia and unexplained fatigue [12].
The awareness about HCV infection, mode of transmission
and clinical presentations is rising among the population. The
link between unexplained presentations and HCV infection
becomes more understandable within the community. The
improvement of knowledge is attributed to the media, health-
care providers and contact to infected persons with HCV
[13,14].
The availability of potent, effective treatment encourages
the treatment of chronic HCV especially with the presence of
specialized centers for treatment of the disease and related
complications with affordable cost on the national and private
bases. The effect of the recent drugs used for treatment of
HCV should be studied more deeply on the improvement of
extrahepatic manifestations of HCV after viral clearance [15].Conflict of Interest
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